Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$8.264M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
310.38%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$3.660M
Q3 2024
Cash
Q3 2024
P/E
-0.7340
Nov 29, 2024 EST
Free Cash Flow
-$9.967M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $100.0K $0.00 $0.00
YoY Change -100.0%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $100.0K $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $8.155M $5.758M $4.072M $1.180M $1.270M $800.0K
YoY Change 41.63% 41.4% 245.08% -7.09% 58.75%
% of Gross Profit
Research & Development $3.232M $1.170M $5.187M $3.707M $1.880M $3.510M
YoY Change 176.24% -77.44% 39.92% 97.18% -46.44%
% of Gross Profit
Depreciation & Amortization $4.000K $206.0K $85.00K $80.00K $20.00K $0.00
YoY Change -98.06% 142.35% 6.25% 300.0%
% of Gross Profit
Operating Expenses $11.39M $6.928M $9.259M $4.888M $3.150M $4.310M
YoY Change 64.36% -25.18% 89.42% 55.17% -26.91%
Operating Profit -$11.39M -$6.928M -$9.259M -$4.788M
YoY Change 64.36% -25.18% 93.38%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense -$1.900M $26.00K -$16.00K -$34.00K -$310.0K $0.00
YoY Change -7407.69% -262.5% -52.94% -89.03%
% of Operating Profit
Other Income/Expense, Net $250.0K $0.00 $61.00K $0.00
YoY Change -100.0%

Income/Loss

Pretax Income

Income Tax

No data

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$13.04M -$7.024M -$9.303M -$4.820M -$3.460M -$4.310M
YoY Change 85.61% -24.5% 93.01% 39.31% -19.72%
Income Tax
% Of Pretax Income
Net Earnings -$13.04M -$7.024M -$9.303M -$4.822M -$3.460M -$4.310M
YoY Change 85.61% -24.5% 92.93% 39.36% -19.72%
Net Earnings / Revenue -4822.0%
Basic Earnings Per Share -$28.25 -$0.69 -$1.42 -$1.07
Diluted Earnings Per Share -$28.25 -$0.69 -$1.42 -$1.07 -$511.8K -$637.6K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $1.808M $3.781M $7.510M $110.0K $3.820M $610.0K
YoY Change -52.18% -49.65% 6727.27% -97.12% 526.23%
Cash & Equivalents $1.808M $3.781M $3.702M $110.0K $3.820M $610.0K
Short-Term Investments $0.00 $3.808M
Other Short-Term Assets $1.126M $371.0K $619.0K $570.0K $100.0K $20.00K
YoY Change 203.5% -40.06% 8.6% 470.0% 400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.934M $4.152M $8.129M $670.0K $3.920M $640.0K
YoY Change -29.34% -48.92% 1113.28% -82.91% 512.5%
Property, Plant & Equipment $22.00K $206.0K $280.0K $350.0K $0.00
YoY Change -26.43% -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $22.00K $0.00 $206.0K $290.0K $360.0K $0.00
YoY Change -100.0% -28.97% -19.44%
Total Assets $2.956M $4.152M $8.335M $960.0K $4.280M $640.0K
YoY Change
Accounts Payable $1.410M $977.0K $918.0K $1.230M $250.0K $290.0K
YoY Change 44.32% 6.43% -25.37% 392.0% -13.79%
Accrued Expenses $750.0K $401.0K $353.0K $640.0K $220.0K $50.00K
YoY Change 87.03% 13.6% -44.84% 190.91% 340.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $97.00K $150.0K $90.00K $0.00
YoY Change -100.0% -35.33% 66.67%
Total Short-Term Liabilities $2.697M $1.810M $2.445M $2.230M $810.0K $490.0K
YoY Change 49.01% -25.97% 9.64% 175.31% 65.31%
Long-Term Debt $0.00 $0.00 $72.00K $180.0K $250.0K $0.00
YoY Change -100.0% -60.0% -28.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $72.00K $180.0K $250.0K $0.00
YoY Change -100.0% -60.0% -28.0%
Total Liabilities $2.697M $1.810M $2.517M $2.410M $1.060M $490.0K
YoY Change 49.01% -28.09% 4.44% 127.36% 116.33%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 461.6K shares 10.14M shares 6.541M shares 4.506M shares
Diluted Shares Outstanding 461.6K shares 10.14M shares 6.541M shares 4.506M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $6.0658 Million

About GRI Bio, Inc.

GRI Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 4 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The firm is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).

Industry: Pharmaceutical Preparations Peers: CNBX Pharmaceuticals Inc. Baudax Bio, Inc. Bespoke Extracts, Inc. Resonate Blends, Inc. NEXIEN BIOPHARMA, INC. JOHNSON & JOHNSON